Development of a childhood leukemia translational research program.
|
Dana-Farber Cancer Institute / Lewis Silverman |
Phase I/II Infrastructure Grants |
2009 |
Massachusetts |
Expanding access to new agents for children with refractory cancers: the experimental therapeutics program at Children's Hospital of Colorado.
|
Children’s Hospital Colorado / Lia Gore, MD |
Phase I/II Infrastructure Grants |
2009 |
Colorado |
Targeting wnt in synovial sarcoma models.
|
Vanderbilt University Medical Center / Josiane Eid |
Innovation Grants |
2009 |
Tennessee |
Adaptation of acute lymphoblastic leukemia (ALL) to the post-transplant allogeneic environment.
|
University of Rochester / Craig Mullen |
Innovation Grants |
2009 |
New York |
BH3 profiling to define therapy resistance classes in neuroblastoma.
|
Children’s Hospital of Philadelphia / Michael Hogarty |
Innovation Grants |
2009 |
Pennsylvania |
Pharmacogenomics of childhood AML susceptibility and treatment response.
|
Children’s Hospital of Philadelphia / Richard Aplenc |
Innovation Grants |
2009 |
Pennsylvania |
Linking mitogenic sonic hedgehog signaling to the oncogene Yap 1 in neural stem/progenitor cells and medulloblastoma.
|
Memorial Sloan-Kettering Cancer Center / Anna Kenney, PhD |
Innovation Grants |
2009 |
New York |
Molecular diagnostic, prognostic, and therapeutic approaches toward Ewing sarcoma.
|
Huntsman Cancer Institute / Stephen Lessnick |
Innovation Grants |
2009 |
Utah |
Targeted regulation of acetylation as novel therapy for Ewing sarcoma.
|
Georgetown University / Jeffrey Toretsky |
Innovation Grants |
2009 |
District of Columbia |
Modeling anaplastic medulloblastoma using cerebellar stem cells
|
Duke University / Robert Wechsler-Reya, PhD |
Innovation Grants |
2009 |
North Carolina |